Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Skye Bioscience, Inc. Common Stock (SKYE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/07/2025: SKYE (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 90.43% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 142.84M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 7 | Beta 1.67 | 52 Weeks Range 1.14 - 7.47 | Updated Date 07/7/2025 |
52 Weeks Range 1.14 - 7.47 | Updated Date 07/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.83 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.04% | Return on Equity (TTM) -47.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 84026052 | Price to Sales(TTM) - |
Enterprise Value 84026052 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.56 | Shares Outstanding 30984400 | Shares Floating 16089248 |
Shares Outstanding 30984400 | Shares Floating 16089248 | ||
Percent Insiders 1.44 | Percent Institutions 80.79 |
Upturn AI SWOT
Skye Bioscience, Inc. Common Stock
Company Overview
History and Background
Skye Bioscience, Inc. (SKYE) is a biopharmaceutical company focused on developing proprietary cannabinoid-based pharmaceutical therapies. Originally founded as Emerald Bioscience, the company shifted its focus and rebranded. The company's history includes research and development efforts in cannabinoid therapeutics for glaucoma and other diseases.
Core Business Areas
- Pharmaceutical Development: Development of cannabinoid-derived drug candidates for various therapeutic applications, primarily focusing on glaucoma.
- Research and Development: Preclinical and clinical research to advance cannabinoid therapeutics.
Leadership and Structure
As of the last update, the executive team consists of key personnel in research, development, and finance. Skye Bioscience operates with a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- SBI-100 Ophthalmic Emulsion: A proprietary formulation of a synthetic cannabinoid derivative designed to reduce intraocular pressure for the treatment of glaucoma. It is currently in clinical trials. Competitors include traditional glaucoma medications (e.g., prostaglandins, beta-blockers) from companies like Allergan (ABBV) and Novartis (NVS). Market share/revenue for this product is currently $0.00, as it is under development.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the segment focused on ophthalmic diseases like glaucoma, is competitive. There is growing interest in novel therapies that can address unmet needs in glaucoma treatment.
Positioning
Skye Bioscience is positioned as a company developing innovative cannabinoid-based therapeutics. The company is attempting to develop drugs that improve on the efficacy and safety of existing treatments.
Total Addressable Market (TAM)
The global glaucoma market is projected to reach $5.9 billion by 2028. Skye Bioscience's position relies on securing a share of this large market through novel therapeutic options.
Upturn SWOT Analysis
Strengths
- Novel cannabinoid-based therapeutic approach
- Proprietary drug formulation
- Focus on unmet needs in glaucoma treatment
Weaknesses
- Limited financial resources
- Early stage of clinical development
- High regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into other therapeutic areas
Threats
- Competition from established pharmaceutical companies
- Regulatory setbacks
- Unfavorable clinical trial outcomes
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- ALX
- SAGE
Competitive Landscape
Skye Bioscience faces significant competition from established pharmaceutical companies with greater resources and approved products. Its success relies on demonstrating superior efficacy and safety with its cannabinoid-based therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by preclinical and clinical development milestones.
Future Projections: Future growth depends on the success of SBI-100 in clinical trials and potential future partnerships and approvals.
Recent Initiatives: Recent strategic initiatives include advancing SBI-100 through clinical trials and exploring additional cannabinoid therapeutic opportunities.
Summary
Skye Bioscience is an early-stage biopharmaceutical company focused on cannabinoid-based therapies. While the company's novel approach to treating glaucoma offers potential, its limited financial resources and early stage of development pose significant risks. Positive clinical trial results and strategic partnerships will be crucial for its future success. It needs to watch out for other companies with more funds or companies that might come out with the same type of therapy.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Skye Bioscience, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-04-02 | President, CEO, Secretary & Director Mr. Punit S. Dhillon B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://skyebioscience.com |
Full time employees 16 | Website https://skyebioscience.com | ||
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.